Reason for request
Inclusion on list of products for hospital use.
Clinical Benefit
Substantial |
The actual benefit of ACTILYSE 2 mg is substantial.
|
Clinical Added Value
minor |
ACTILYSE 2 mg provides a minor improvement in actual benefit (IAB IV) in terms of efficacy in comparison with ACTOSOLV UROKINASE.
|
eNq1mF1v2jAUhu/5FVHuiQstlE6BamOwIbUqo0WbdoNMcgBnxk79AXS/fg6hGp0cdTX1ZWLnPSc+rx8fOb7erWmwASEJZ92wEZ2FAbCEp4Qtu+H0YVjvhNe9WpzhDT6aZuZFzWYYJBRL2Q2L0WgOmMnox+3NZzDfgwh7tSDm8wwS9WKeVoRGX7Fc3eK8mBPEG07SYA1qxdNumGu1fxvEUgmTRW/LxS+Z4wRidHhzPJrNLo7fx6gQ+w9VLUHcYLa0igJz0ky0EMBUHytYcvFUke+5kzaRE5BciwTGWK3Ggm9ICqk1xAJTCU5BFtv0HsSGgiqCWMVRlqylkzjO8G4CjyN70h/NaF/tVP2s3rhsXFxetDut5nm74xRKHC2VvQrmJ1Ay67Tbl1dNBAxlElEyR0BhbSr4TYN4ijLpWKkxFwpTTzUisv/SZp7iCHh81QspkTnFxUrlrkuFBTbDIAwM/P1I8QcPwuCJmjX7R59pStEbs54e4OEp44JNfa6ZqmDIcOK6EH3OFOyqK+qGPbU7eJGAfD/Z35zZkT/Wc0oSV8AZBGmQajoZVfPNHxo+YQlT4Y8N3wlL+Va+P3OOa+wp+3yPTatoLtLGrHnVaTdaLect9dMYquL0GWjBc0CGRkSeApkRW/BT8WI8apd6dqgnc+47Ip5gChU90cyRO8aVzy2cN9/721PlgFX0y+DB1Sz7St3vH63SJO0+l9mNyT5Ab5xZmffbfV5udy/NshZ2jKyUyuUHhLbbbbTCsi6xWaVoITxD/+jU9de4eznay1anBKen1Oflifi2erluu9cO/1Mb2sP3h8bZGkMJDSfUoiS0N46OBu+P5r/drLe0xy9Y4i/MvvPEinDmqwfSc6viSYeBKSsbCsOHu8WCVNyjVNoyRuUdTq8Wo+L+plf7A6ow+jk=
fdALbZRY8Q4bbTtE